Supernus Pharmaceuticals SUPN Fair Value Measurement Disclosure
Fair Value Measurement Disclosure at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue.
The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Supernus Pharmaceuticals's fair value measurement disclosure.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Supernus Pharmaceuticals's fair value measurement disclosure?
- Supernus Pharmaceuticals (SUPN) reported fair value measurement disclosure of $206K in Q1 2026.
- How has Supernus Pharmaceuticals's fair value measurement disclosure changed year-over-year?
- Supernus Pharmaceuticals's fair value measurement disclosure decreased by 99.3% year-over-year, from $30M to $206K.
- What is the long-term trend for Supernus Pharmaceuticals's fair value measurement disclosure?
- Over 5 years (2020 to 2025), Supernus Pharmaceuticals's fair value measurement disclosure has grown at a -16.4% compound annual growth rate (CAGR), from $76.7M to $31.26M.
- What does fair value measurement disclosure mean?
- This represents the aggregate carrying amount of assets and liabilities that are measured at fair value on a recurring or non-recurring basis. It provides transparency into the valuation techniques and inputs used to determine these values, categorized by the fair value hierarchy. This is critical for asset managers holding diverse investment portfolios.